{"id":510,"date":"2024-07-22T15:16:23","date_gmt":"2024-07-22T15:16:23","guid":{"rendered":"http:\/\/nouveausiteintegragen2.local\/?page_id=510"},"modified":"2025-07-01T15:24:01","modified_gmt":"2025-07-01T13:24:01","slug":"communiques-de-presse-archives","status":"publish","type":"page","link":"https:\/\/integragen.com\/en\/investisseurs\/archives\/communiques-de-presse-archives\/","title":{"rendered":"Archived Press Releases"},"content":{"rendered":"<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-7a3688e9 wp-block-group-is-layout-constrained\">\n<div style=\"height:8px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"cozy-block-wrapper\">\n<ul class=\"cozy-block-icon-list vertical default fill\" id=\"cozyBlock_c1299c08_6389_4b0e_8bb0_fbd6dd67f7ff\">\n<div class=\"list-inline-block\"><a href=\"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/\" target=\"\" rel=\"noopener\"><li class=\"cozy-block-list-item\" id=\"cozyBlock_d7d842b5_e8a8_4b1c_b051_4bbbcb91ed26\"><div class=\"list-icon-wrapper\"><svg viewbox=\"0 0 20 10\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\"><path d=\"M15.1109 1.11091C15.5014 0.720385 16.1346 0.720385 16.5251 1.11091L19.7071 4.29289C20.0976 4.68341 20.0976 5.31658 19.7071 5.7071L16.5251 8.88908C16.1346 9.27961 15.5014 9.27961 15.1109 8.88908C14.7204 8.49856 14.7204 7.86539 15.1109 7.47487L16.5858 6H0.5V4H16.5858L15.1109 2.52512C14.7204 2.1346 14.7204 1.50143 15.1109 1.11091Z\"><\/path><\/svg><\/div><p>Back<\/p><\/li><\/a><\/div>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:8px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\">Archived Press Releases<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2020<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>16\/11\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201116005947\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Successful friendly takeover bid by OncoDNA for IntegraGen shares<\/a><\/td><\/tr><tr><td>18\/09\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20200917006022\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2020 results<\/a><\/td><\/tr><tr><td>09\/07\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20200708005949\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Agreement on a friendly takeover bid by OncoDNA for IIntegraGen<\/a><\/td><\/tr><tr><td>03\/04\/2020<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/cp_integragen_rn-2019_final_030420-corrected.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Annual results 2019<\/a><\/td><\/tr><tr><td>26\/03\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20200326005547\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces agreement with leading US cancer center to use MERCURY\u2122<\/a><\/td><\/tr><tr><td>11\/03\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20200311005625\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen renews partnership agreement with Institut Pasteur<\/a><\/td><\/tr><tr><td>10\/01\/2020<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20200109005819\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 2019 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2019<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>23\/09\/2019<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20190922005046\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2019 results<\/a><\/td><\/tr><tr><td>11\/07\/2019<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20190711005554\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Sales of \u20ac4.2m in the first half of 2019, up +151TP3Q<\/a><\/td><\/tr><tr><td>18\/04\/2019<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20190417005986\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Annual results 2018<\/a><\/td><\/tr><tr><td>05\/03\/2019<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20190304005933\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen and Advanced Biological Laboratories announce the signing of a global license agreement for the commercialization of the miRpredX\u2122 assay.<\/a><\/td><\/tr><tr><td>09\/01\/2019<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20190109005636\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 2018 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2018<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-custom-couleur-1-color has-text-color has-link-color has-fixed-layout\"><tbody><tr><td>12\/11\/2018<\/td><td><a href=\"https:\/\/integragen.com\/wp-admin\/post.php?post=1783&amp;action=edit\">I<\/a><a href=\"https:\/\/www.businesswire.com\/news\/home\/20181112005568\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">ntegraGen announces collaboration with Google Cloud to bring its large-scale sequencing data analysis tools to clinicians and researchers<\/a><\/td><\/tr><tr><td>20\/09\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180920005659\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2018 results<\/a><\/td><\/tr><tr><td>04\/09\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180903005333\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Publication of the results of the FIRE-3 study in Clinical Cancer Research, highlighting the potential of the miR-31-3p biomarker to select the treatment best suited to the genetic profile of patients with metastatic colorectal cancer.<\/a><\/td><\/tr><tr><td>31\/07\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180730005858\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">GCS SeqOIA chooses IntegraGen to operate its sequencing platform as part of the France Genomic Medicine 2025 Plan<\/a><\/td><\/tr><tr><td>10\/07\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180708005021\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Sales growth at June 30, 2018: +17%<\/a><\/td><\/tr><tr><td>23\/04\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180423005988\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen obtains ISO 13485:2016 certification for the design, production and distribution of in vitro diagnostic kits<\/a><\/td><\/tr><tr><td>13\/04\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180412006357\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 2017 annual results: sustained momentum in clinical genomics services and improved net income.<\/a><\/td><\/tr><tr><td>12\/04\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180411006407\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presents results of study on circulating microRNAs as predictive markers of treatment response at European Lung Cancer Conference 2018<\/a><\/td><\/tr><tr><td>14\/02\/2018<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/2018-02-14-integragen-twist-bioscience-sirius-mercury-vf-13feb-1.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen and Twist Bioscience extend partnership with distribution agreement for genomic analysis tools, SIRIUS and MERCURY<\/a><\/td><\/tr><tr><td>25\/01\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180124006271\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen joins forces with Twist Bioscience<\/a><\/td><\/tr><tr><td>18\/01\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180118006086\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen launches two Big Data solutions for high-performance exploration of large-scale genomic data: SIRIUS\u2122 and MERCURY\u2122<\/a><\/td><\/tr><tr><td>09\/01\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180109006518\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 2017 sales and cash position<\/a><\/td><\/tr><tr><td>09\/01\/2018<\/td><td><a href=\"https:\/\/www.businesswire.com\/news\/home\/20180109006413\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen and GoPath Laboratories announce the signature of a license agreement for the commercialization of the miR-31-3p test in North America.<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2017<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>30\/10\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20171030005304\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen receives Galien MedStartUp award for its collaboration with The Solution Lab on ICE software<\/a><\/td><\/tr><tr><td>09\/10\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20171008005051\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces publication of miR-31-3p data at&nbsp;<em>Oncotarget<\/em><\/a><\/td><\/tr><tr><td>28\/09\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170928005976\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2017 results<\/a><\/td><\/tr><tr><td>07\/09\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170907006192\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces CE-IVD marking of miRpredX 31-3p kit<\/a><\/td><\/tr><tr><td>11\/07\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170710006324\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Continued strong growth in the first half of 2017<\/a><\/td><\/tr><tr><td>21\/04\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170420006688\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces financial results for 2016<\/a><\/td><\/tr><tr><td>08\/03\/2017<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/2017-03-08-cerba-integragen-press-release-licensing-agreement-french.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">CERBA Laboratory and IntegraGen sign licensing agreement for miR-31-3p assay<\/a><\/td><\/tr><tr><td>03\/02\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170202006425\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Successful completion of \u20ac3.7m capital increase<\/a><\/td><\/tr><tr><td>09\/01\/2017<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20170109006045\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sales 2016<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2016<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>14\/10\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20161013006423\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2016 results<\/a><\/td><\/tr><tr><td>10\/10\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20161010005830\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presented new positive efficacy data for the miR-31-3p biomarker at the 2016 ESMO Congress<\/a><\/td><\/tr><tr><td>07\/07\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160706006421\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Strong sales growth in the 1<sup>er<\/sup>&nbsp;half-year 2016<\/a><\/td><\/tr><tr><td>29\/06\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160629006255\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">AP-HP and IntegraGen to develop a joint ultra-high-throughput sequencing platform<\/a><\/td><\/tr><tr><td>06\/06\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160605005123\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presents positive results at ASCO 2016 on miR-31-3p biomarker<\/a><\/td><\/tr><tr><td>08\/04\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160407006326\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces financial results for 2015<\/a><\/td><\/tr><tr><td>14\/01\/2016<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160113006187\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sales 2015<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2015<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>02\/12\/2015<\/td><td><a href=\"http:\/\/goo.gl\/WDgA9H\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces collaboration with FIRE 3 investigators to validate hsa-miR-31-3p biomarker in metastatic colorectal cancer<\/a><\/td><\/tr><tr><td>17\/11\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20151116006705\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gustave Roussy and IntegraGen announce the completion of over a thousand analyses in less than eighteen months on their joint sequencing platform for clinical research.<\/a><\/td><\/tr><tr><td>02\/10\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20151001006683\/fr\/#.Vg4oCXpViko\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2015 results<\/a><\/td><\/tr><tr><td>25\/08\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150825006040\/fr\/#.VdyWkfZViko\" target=\"_blank\" rel=\"noreferrer noopener\">Results of Integragen's sequencing of 193 liver tumors identify a new virus involved in the development of liver cancer<\/a><\/td><\/tr><tr><td>10\/07\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150709006115\/fr#.VZ_TYPlViko\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2015 sales<\/a><\/td><\/tr><tr><td>08\/07\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150707006310\/fr#.VZy-L_lViko\" target=\"_blank\" rel=\"noreferrer noopener\">AP-HP: H\u00f4pital Europ\u00e9en Georges Pompidou and IntegraGen announce cooperation agreement&nbsp;<\/a><\/td><\/tr><tr><td>07\/07\/2015<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/2015-07-03-integragen_cp_emission-actions-nouvelles_paceo_fr-version-definitive.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen : Issuance of new shares<\/a><\/td><\/tr><tr><td>01\/06\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150601006332\/fr\" target=\"_blank\" rel=\"noreferrer noopener\">At ASCO, IntegraGen announces positive results from two new studies on the role of the biomarker miR-31-3p<\/a><\/td><\/tr><tr><td>05\/05\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150505006446\/fr\/#.VUmzu_lViko\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen secures optional equity financing<\/a><\/td><\/tr><tr><td>10\/04\/2015<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/integragen_cp_rn_2014_vf_fr.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen: 12% sales growth in 2014<\/a><\/td><\/tr><tr><td>27\/03\/2015<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/integragen-reaffirme-eligibilite-au-pea-pme.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen reaffirms its PEA-PME eligibility<\/a><\/td><\/tr><tr><td>24\/03\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150324006411\/fr\/#.VSR-cfnF-Sp\" target=\"_blank\" rel=\"noreferrer noopener\">Institut Pasteur joins forces with IntegraGen to strengthen its high throughput sequencing activities in microbiology<\/a><\/td><\/tr><tr><td>05\/02\/2015<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150205005958\/fr\/#.VSR-3_nF-Sp\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces distribution agreement for its autism predisposition test<\/a><\/td><\/tr><tr><td>08\/01\/2015<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/communique_bilan_contrat_liquidite_s2_2014.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Annual review of the liquidity contract<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2014<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>16\/12\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20141215006564\/fr\/#.VSSFSfnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen and PICCOLO trial investigators announce collaboration agreement to validate role of Hsa-miR-31-3p biomarker in metastatic colorectal cancer<\/a><\/td><\/tr><tr><td>02\/12\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20141201006150\/fr\/#.VSSGhfnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen awarded worldwide licensing rights for two molecular signatures in liver cancer.<\/a><\/td><\/tr><tr><td>07\/10\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20141006006562\/fr\/#.VSSHAfnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2014 results<\/a><\/td><\/tr><tr><td>30\/09\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140929006403\/fr\/#.VSSHQfnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presents data at ESMO confirming that its microRNA biomarker is predictive of the effect of anti-EGFR treatment in patients with metastatic colorectal cancer<\/a><\/td><\/tr><tr><td>02\/09\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140901005458\/fr\/#.VSSHmvnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces collaboration with the Intergroupe Francophone de Canc\u00e9rologie Thoracique (IFCT) to explore the use of the miR-31-3p biomarker in non-small cell lung cancer<\/a><\/td><\/tr><tr><td>16\/07\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20141006006562\/fr\/#.VSSIN_nF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 1st half 2014 results<\/a><\/td><\/tr><tr><td>23\/06\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140622005083\/fr\/#.VSSKg_nF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen, Gustave Roussy, Inserm and Sogeti High Tech announce the development of scientific software to help interpret genomic sequencing data and revolutionize cancer diagnostics<\/a><\/td><\/tr><tr><td>12\/06\/2014<\/td><td><a href=\"https:\/\/www.euronext.com\/fr\/content\/integragen-tr%C3%A8s-vif-succ%C3%A8s-de-l%E2%80%99augmentation-de-capital\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen: Very successful capital increase<\/a><\/td><\/tr><tr><td>02\/06\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140601005090\/fr\/#.VSSLKvnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presents bio-marker data at ASCO to predict treatment effect in colorectal cancer patients<\/a><\/td><\/tr><tr><td>19\/05\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140518005082\/fr\/#.VSSLZPnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen presents data from a new version of the ARISk\u00ae test at the 13th annual IMFAR conference<\/a><\/td><\/tr><tr><td>15\/05\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140514006948\/fr\/#.VSSLr_nF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen: Publication of a study demonstrating the correlation between progression-free survival of patients treated with anti-EGFR for metastatic colorectal cancer and the level of expression of the hsa-mi-31-3p biomarker in the tumor<\/a><\/td><\/tr><tr><td>11\/04\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140410006554\/fr\/#.VSSL9fnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - Annual results 2013<\/a><\/td><\/tr><tr><td>03\/04\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140402006869\/fr\/#.VSSMUPnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces a collaboration agreement with Pfizer to evaluate the value of its molecular signature in hepatocellular carcinoma<\/a><\/td><\/tr><tr><td>24\/03\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140324005488\/fr\/#.VSSNPPnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen and Gustave Roussy announce the creation of an ultra-high-throughput clinical sequencing unit&nbsp;<\/a><\/td><\/tr><tr><td>21\/02\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140220006721\/fr\/#.VSSNzfnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces publication of a study reconfirming the association of common genetic variants with autism<\/a><\/td><\/tr><tr><td>14\/01\/2014<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20140113006722\/fr\/#.VSSOLPnF-So\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces collaboration with New EPOC investigators to validate a biomarker in metastatic colorectal cancer<\/a><\/td><\/tr><tr><td>09\/01\/2014<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/communique_bilan_contrat_liquidite_s2_2013.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Annual review of the liquidity contract<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2013<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>19\/12\/2013<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20131218006582\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen carries out the sequencing of more than one hundred breast cancer metastases, and a French team presents its results.<\/a><\/td><\/tr><tr><td>29\/10\/2013<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20131029005812\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen announces the results of a study on a new version of the ARISk\u00ae test to identify the risk of autism in cases of suspected or delayed development.<\/a><\/td><\/tr><tr><td>22\/10\/2013<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20131022006513\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">1st half 2013 results<\/a><\/td><\/tr><tr><td>14\/10\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/press-release-mir-31-3p-license.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Netastatic colorectal cancer: Exclusive license<\/a><\/td><\/tr><tr><td>29\/09\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/press-release-mir-31-3p-license.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Continuous quotation of IntegraGen shares<\/a><\/td><\/tr><tr><td>08\/07\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/2013-s1-results.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">First-half 2013 sales<\/a><\/td><\/tr><tr><td>08\/07\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/communique_bilan_contrat_liquidite_s1_2013.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Liquidity contract for H1 2013<\/a><\/td><\/tr><tr><td>07\/07\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/press-release-gastroenterology-publication-2013.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Publication of a joint study by Inserm, La Ligue and Integragen: \"Gastroenterology journal\".<\/a><\/td><\/tr><tr><td>01\/07\/2013<\/td><td><a href=\"http:\/\/www.france-biotech.org\/integragen-envisage-un-placement-prive\/\" target=\"_blank\" rel=\"noreferrer noopener\">Capital increase<\/a><\/td><\/tr><tr><td>15\/04\/2013<\/td><td><a href=\"https:\/\/integragen.com\/wp-content\/uploads\/press-release-results-annual-2012.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">2012 annual results<\/a><\/td><\/tr><tr><td>08\/01\/2013<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20130108006849\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Half-yearly report on the liquidity contract<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2012<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>28\/11\/2012<\/td><td><a href=\"http:\/\/cpj.sagepub.com\/content\/52\/2\/139.full.pdf+html\" target=\"_blank\" rel=\"noreferrer noopener\">Autism: Results of a parental survey<\/a><\/td><\/tr><tr><td>29\/10\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20121029006268\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">1st half 2012 results<\/a><\/td><\/tr><tr><td>11\/07\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120711006149\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Half-yearly report on the liquidity contract<\/a><\/td><\/tr><tr><td>10\/07\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120710006532\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Successful reserved capital increase<\/a><\/td><\/tr><tr><td>29\/05\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120529005628\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 57 new genetic markers linked to autism identified<\/a><\/td><\/tr><tr><td>23\/04\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120423005555\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen - 2011 Annual Results<\/a><\/td><\/tr><tr><td>05\/04\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120405006122\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">IntegraGen launches ARISk\u2122 test in the US, a genetic tool for autism risk assessment<\/a><\/td><\/tr><tr><td>14\/03\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120314005637\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Launch of a study in the United States to develop a genetic test for earlier diagnosis of autism<\/a><\/td><\/tr><tr><td>06\/03\/2012<\/td><td><a href=\"https:\/\/integragen.com\/en\/fr\/investisseurs\/communiques-de-presse\/CA%20en%20tr%C3%A8s%20forte%20croissance%20pour%202011\/\" target=\"_blank\" rel=\"noreferrer noopener\">Very strong sales growth for 2011<\/a><\/td><\/tr><tr><td>06\/01\/2012<\/td><td><a href=\"http:\/\/www.businesswire.com\/news\/home\/20120106005617\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Half-yearly report on the liquidity contract<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Press Releases Archived 2020 16\/11\/2020 Successful friendly takeover bid initiated by OncoDNA for IntegraGen shares 18\/09\/2020 IntegraGen - 1st half 2020 results 09\/07\/2020 Agreement for a friendly takeover bid initiated by OncoDNA for IIntegraGen 03\/04\/2020 IntegraGen - 2019 annual results 26\/03\/2020 IntegraGen announces an agreement with a...<\/p>","protected":false},"author":1,"featured_media":0,"parent":429,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"fullwidth-page-template","meta":{"ca_portfolio_gallery_project_year":"","ca_portfolio_gallery_client":"","ca_portfolio_gallery_skills":"","ca_portfolio_gallery_url":"","ca_portfolio_gallery_images":"","_eb_attr":"","footnotes":""},"class_list":["post-510","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/integragen.com\/en\/investisseurs\/archives\/communiques-de-presse-archives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen\" \/>\n<meta property=\"og:description\" content=\"Communiqu\u00e9s de Presse Archiv\u00e9s 2020 16\/11\/2020 Succ\u00e8s de l\u2019offre publique d\u2019achat amicale initi\u00e9e par OncoDNA sur les actions IntegraGen 18\/09\/2020 IntegraGen \u2013 R\u00e9sultats du 1er semestre 2020 09\/07\/2020 Accord en vue d\u2019une offre publique d\u2019achat amicale initi\u00e9e par OncoDNA sur IIntegraGen 03\/04\/2020 IntegraGen \u2013 R\u00e9sultats annuels 2019 26\/03\/2020 IntegraGen annonce un accord avec un centre...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/integragen.com\/en\/investisseurs\/archives\/communiques-de-presse-archives\/\" \/>\n<meta property=\"og:site_name\" content=\"IntegraGen\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-01T13:24:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/image-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2478\" \/>\n\t<meta property=\"og:image:height\" content=\"684\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/communiques-de-presse-archives\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/communiques-de-presse-archives\\\/\",\"name\":\"Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\"},\"datePublished\":\"2024-07-22T15:16:23+00:00\",\"dateModified\":\"2025-07-01T13:24:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/communiques-de-presse-archives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/communiques-de-presse-archives\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/communiques-de-presse-archives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/integragen.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investisseurs\",\"item\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Archives\",\"item\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/archives\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Communiqu\u00e9s de Presse Archiv\u00e9s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"name\":\"IntegraGen - Clinical Genomic Experts\",\"description\":\"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CRO\",\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"alternateName\":\"IntegraGen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/integragen.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\",\"name\":\"IntegraGen\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"width\":2478,\"height\":684,\"caption\":\"IntegraGen\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/integragen\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/integragen.com\/en\/investisseurs\/archives\/communiques-de-presse-archives\/","og_locale":"en_US","og_type":"article","og_title":"Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen","og_description":"Communiqu\u00e9s de Presse Archiv\u00e9s 2020 16\/11\/2020 Succ\u00e8s de l\u2019offre publique d\u2019achat amicale initi\u00e9e par OncoDNA sur les actions IntegraGen 18\/09\/2020 IntegraGen \u2013 R\u00e9sultats du 1er semestre 2020 09\/07\/2020 Accord en vue d\u2019une offre publique d\u2019achat amicale initi\u00e9e par OncoDNA sur IIntegraGen 03\/04\/2020 IntegraGen \u2013 R\u00e9sultats annuels 2019 26\/03\/2020 IntegraGen annonce un accord avec un centre...","og_url":"https:\/\/integragen.com\/en\/investisseurs\/archives\/communiques-de-presse-archives\/","og_site_name":"IntegraGen","article_modified_time":"2025-07-01T13:24:01+00:00","og_image":[{"width":2478,"height":684,"url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/image-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/integragen.com\/investisseurs\/archives\/communiques-de-presse-archives\/","url":"https:\/\/integragen.com\/investisseurs\/archives\/communiques-de-presse-archives\/","name":"Communiqu\u00e9s de Presse Archiv\u00e9s &#8211; IntegraGen","isPartOf":{"@id":"https:\/\/integragen.com\/#website"},"datePublished":"2024-07-22T15:16:23+00:00","dateModified":"2025-07-01T13:24:01+00:00","breadcrumb":{"@id":"https:\/\/integragen.com\/investisseurs\/archives\/communiques-de-presse-archives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/integragen.com\/investisseurs\/archives\/communiques-de-presse-archives\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/integragen.com\/investisseurs\/archives\/communiques-de-presse-archives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/integragen.com\/"},{"@type":"ListItem","position":2,"name":"Investisseurs","item":"https:\/\/integragen.com\/investisseurs\/"},{"@type":"ListItem","position":3,"name":"Archives","item":"https:\/\/integragen.com\/investisseurs\/archives\/"},{"@type":"ListItem","position":4,"name":"Communiqu\u00e9s de Presse Archiv\u00e9s"}]},{"@type":"WebSite","@id":"https:\/\/integragen.com\/#website","url":"https:\/\/integragen.com\/","name":"IntegraGen - Clinical Genomic Experts","description":"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CROs","publisher":{"@id":"https:\/\/integragen.com\/#organization"},"alternateName":"IntegraGen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/integragen.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/integragen.com\/#organization","name":"IntegraGen","url":"https:\/\/integragen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/","url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","width":2478,"height":684,"caption":"IntegraGen"},"image":{"@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/integragen\/"]}]}},"_links":{"self":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/comments?post=510"}],"version-history":[{"count":2,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/510\/revisions"}],"predecessor-version":[{"id":4323,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/510\/revisions\/4323"}],"up":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/429"}],"wp:attachment":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/media?parent=510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}